Protagonist Therapeutics PTGX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's total operating expenses?
- Protagonist Therapeutics (PTGX) reported total operating expenses of $60.02M in Q1 2026.
- How has Protagonist Therapeutics's total operating expenses changed year-over-year?
- Protagonist Therapeutics's total operating expenses increased by 26.0% year-over-year, from $47.63M to $60.02M.
- What is the long-term trend for Protagonist Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's total operating expenses has grown at a 7.4% compound annual growth rate (CAGR), from $153.2M to $204.14M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.